Jeremy A Slivnick,Will Hawkes,Jorge Oliveira,Gary Woodward,Ashley Akerman,Alberto Gomez,Izhan Hamza,Viral K Desai,Zachary Barrett-O'Keefe,Martha Grogan,Angela Dispenzieri,Christopher G Scott,Halley N Davison,Juan Cotella,Mathew Maurer,Stephen Helmke,Marielle Scherrer-Crosbie,Marwa Soltani,Akash Goyal,Karolina M Zareba,Richard K Cheng,James N Kirkpatrick,Tetsuji Kitano,Masaaki Takeuchi,Viviane Tiemi Hotta,Marcelo Luiz Campos Vieira,Pablo Elissamburu,Ricardo E Ronderos,Aldo Prado,Efstratios Koutroumpakis,Anita Deswal,Amit Pursnani,Nitasha Sarswat,Amit R Patel,Karima Addetia,Frederick L Ruberg,Michael Randazzo,Federico M Asch,Jamie O'Driscoll,Nora Al-Roub,Jordan B Strom,Liam Kidd,Sarah Cuddy,Ross Upton,Roberto M Lang,Patricia A Pellikka
{"title":"Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.","authors":"Jeremy A Slivnick,Will Hawkes,Jorge Oliveira,Gary Woodward,Ashley Akerman,Alberto Gomez,Izhan Hamza,Viral K Desai,Zachary Barrett-O'Keefe,Martha Grogan,Angela Dispenzieri,Christopher G Scott,Halley N Davison,Juan Cotella,Mathew Maurer,Stephen Helmke,Marielle Scherrer-Crosbie,Marwa Soltani,Akash Goyal,Karolina M Zareba,Richard K Cheng,James N Kirkpatrick,Tetsuji Kitano,Masaaki Takeuchi,Viviane Tiemi Hotta,Marcelo Luiz Campos Vieira,Pablo Elissamburu,Ricardo E Ronderos,Aldo Prado,Efstratios Koutroumpakis,Anita Deswal,Amit Pursnani,Nitasha Sarswat,Amit R Patel,Karima Addetia,Frederick L Ruberg,Michael Randazzo,Federico M Asch,Jamie O'Driscoll,Nora Al-Roub,Jordan B Strom,Liam Kidd,Sarah Cuddy,Ross Upton,Roberto M Lang,Patricia A Pellikka","doi":"10.1093/eurheartj/ehaf387","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND AIMS\r\nAccurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed.\r\n\r\nMETHODS\r\nUtilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness.\r\n\r\nRESULTS\r\nCardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores.\r\n\r\nCONCLUSIONS\r\nThis AI screening model-using only an apical four-chamber view-effectively differentiated CA from other causes of increased left ventricular wall thickness.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"109 1","pages":""},"PeriodicalIF":35.6000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurheartj/ehaf387","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND AND AIMS
Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed.
METHODS
Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness.
RESULTS
Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores.
CONCLUSIONS
This AI screening model-using only an apical four-chamber view-effectively differentiated CA from other causes of increased left ventricular wall thickness.
期刊介绍:
The European Heart Journal is a renowned international journal that focuses on cardiovascular medicine. It is published weekly and is the official journal of the European Society of Cardiology. This peer-reviewed journal is committed to publishing high-quality clinical and scientific material pertaining to all aspects of cardiovascular medicine. It covers a diverse range of topics including research findings, technical evaluations, and reviews. Moreover, the journal serves as a platform for the exchange of information and discussions on various aspects of cardiovascular medicine, including educational matters.
In addition to original papers on cardiovascular medicine and surgery, the European Heart Journal also presents reviews, clinical perspectives, ESC Guidelines, and editorial articles that highlight recent advancements in cardiology. Additionally, the journal actively encourages readers to share their thoughts and opinions through correspondence.